login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
SUPERNUS PHARMACEUTICALS INC (SUPN) Stock News
USA
- NASDAQ:SUPN -
US8684591089
-
Common Stock
49.075
USD
+0.7 (+1.44%)
Last: 10/14/2025, 1:05:50 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
SUPN Latest News, Press Relases and Analysis
All
Press Releases
7 days ago - By: Chartmill
SUPERNUS PHARMACEUTICALS INC (NASDAQ:SUPN) Represents an Affordable Growth Opportunity
a day ago - By: Zacks Investment Research
Supernus Pharmaceuticals (SUPN) Is Up 2.81% in One Week: What You Should Know
4 days ago - By: Zacks Investment Research
- Mentions:
NVS
BIIB
PTCT
Can Biogen Stock Rebound as New Drugs Aim to Offset MS Sales Declines?
5 days ago - By: Benzinga
- Mentions:
KTOS
TSCO
PNC
SF
...
Crowdstrike To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Thursday
15 days ago - By: Benzinga
- Mentions:
FTXH
MIXJ
IHE
PBE
...
Pharma ETFs In A Tariff Storm: How Investors Can Hedge Risk
a month ago - By: Biogen Inc.
- Mentions:
BIIB
Biogen Receives European Commission Approval for ZURZUVAE® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe
2 months ago - By: Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals to Participate in September Investor Conferences
2 months ago - By: Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals to Participate in September Investor Conferences
2 months ago - By: Yahoo Finance
Here’s Third Avenue Small-Cap Value Fund’s Update on Supernus Pharmaceuticals (SUPN)
2 months ago - By: Zacks Investment Research
Supernus (SUPN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
2 months ago - By: Zacks Investment Research
- Mentions:
LXRX
Supernus Pharmaceuticals (SUPN) Surpasses Q2 Earnings and Revenue Estimates
2 months ago - By: Supernus Pharmaceuticals, Inc.
Supernus Announces Second Quarter 2025 Financial Results
2 months ago - By: Supernus Pharmaceuticals, Inc.
Supernus Announces Second Quarter 2025 Financial Results
Please enable JavaScript to continue using this application.